SMC accepts fentanyl single dose nasal spray
17th January 2012
The Scottish Medicines Consortium (SMC) has accepted fentanyl single dose nasal spray (Instanyl®, Nycomed) for use within NHS Scotland for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Its use is restricted to patients who are unsuitable for other short-acting oral opioids (e.g. oral morphine) as an alternative to other buccal and sublingual fentanyl preparations.
Recent news
- Morphine manifesto
- EAPC guidelines on the use of opioid analgesics for cancer pain
- MHRA consult on loperamide classification from P to GSL
- Revised patient guide on advance care planning
- MHRA warns against Butterbur herbal remedies
- FDA approve generic morphine sulphate m/r capsules
- Discontinuation of granisetron (Kytril) infusion 1mg/mL
- SMC accepts fentanyl single dose nasal spray
- Crush resistant formulation of oxymorphone approved in US
- NICE end of life care commissioning guide
News archive
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000